BridgeBio Oncology Therapeutics(BBOT)
$2.56+0.36 (+16.36%)
BBOT
BridgeBio Oncology Therapeutics financials statements
$2.56
At close:+0.36 (+16.36%)
Want to see BBOT full AI Analyst Report?
BridgeBio Oncology Therapeutics (BBOT) Ratios
78 Followers
BridgeBio Oncology Therapeutics Ratios
BBOT's free cash flow for Q2 2026 was $-44.41M. For the 2026 fiscal year, BBOT's free cash flow was decreased by $-47.00K and operating cash flow was $-44.36M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.14 | 10.40 | 0.00 | 0.00 | 0.00 |
| Quick Ratio | 12.14 | 10.40 | 0.00 | 0.00 | 0.00 |
| Cash Ratio | 10.66 | 9.05 | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | -3.58 | -12.98 | -162.96 | -0.02 | -0.27 |
| Operating Cash Flow Ratio | -3.25 | -4.07 | 0.00 | 0.00 | 0.00 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 388.18M | $ -3.76M | $ -396.46K | $ -166.46K | $ -162.64K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.21 | 0.30 | 0.26 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | -1.10 | -1.97 | -2.01 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 10.74 | 2.03 | 1.99 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.03 | -5.24 | -6.61 | -7.86 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -922.73 | -0.08 | -1.17 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 2.55 | 0.02 | -0.00 | -12.25 | -0.85 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 91.92% | 91.85% | 99.89% | 100.00% | 100.00% |
| Return on Assets (ROA) | -29.90% | -38.20% | -19435.32% | -2.43% | -30.05% |
| Return on Equity (ROE) | -32.61% | -39.36% | 101777.60% | 16.09% | 236.19% |
| Return on Capital Employed (ROCE) | -35.28% | -41.63% | 101890.86% | 16.09% | 236.19% |
| Return on Invested Capital (ROIC) | -35.23% | -41.63% | -992506.90% | -16.58% | -233.05% |
| Return on Tangible Assets | -29.90% | -38.20% | -19435.32% | -2.43% | -30.05% |
| Earnings Yield | -34.38% | -42.52% | -30.99% | -0.00% | -0.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.66 | -0.05 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Per Share | -3.68 | -0.05 | 0.00 | 0.00 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | -187.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -187.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -41.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -29.36% | -0.44% | 0.00% | 0.00% | 0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.91 | -2.35 | -3.23 | -59301.75 | -4814.50 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.95 | 0.93 | -3283.71 | -9541.63 | -11371.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.41 | -228.69 | 0.00 | 0.00 | 0.00 |
| Price-to-Operating Cash Flow Ratio | -3.42 | -228.69 | 0.00 | 0.00 | 0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.02 | 0.00 | 593.02 | 0.00 |
| Enterprise Value Multiple | -0.13 | -2.14 | -3.23 | -59313.99 | -4815.35 |
| Enterprise Value | 19.01M | 172.98M | 208.81M | 208.79M | 208.78M |
| EV to EBITDA | -0.13 | -2.14 | -3.23 | -59313.99 | -4815.35 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.17 | -226.47 | 0.00 | 0.00 | 0.00 |
| EV to Operating Cash Flow | -0.17 | -226.47 | 0.00 | 0.00 | 0.00 |
| Tangible Book Value Per Share | 13.20 | 11.34 | -0.00 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | 13.20 | 11.34 | -0.00 | -0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.30 | -4.46 | -3.16 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.92 | 0.92 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | -0.10 | 0.00 | 0.00 | 0.00 |
Currency in USD
